Ficerafusp alfa 750 mg QW and pembrolizumab in HPV-negative first-line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

ficerafusp alfa (BCA101) - Biocon

Keytruda (pembrolizumab) - Merck (MSD)

https://oncologypro.esmo.org/congress-resources/esmo-asia-congress-2025?presentation=ficerafusp_alfa_750_mg_qw_and_pembrolizumab_in_hpv

J.M. Kaczmar1; N. Akhave2; T. Sussman3; G.J. Hanna4; A.G. Sacco5; E.J. Sherman6; D.P. Zandberg7; A. Birnbaum8; D.J. Wong9; A. Gupta10; J. Hayman11; Z. Yang12; C.H. Chung13

Oct 4, 2025